News Archives - Page 738 of 779

FridayAug 17, 2018 12:03 pm

NUGL Inc. (NUGL) Cannabis Brand Locator, Profile App Set to Sweep North America

Comprehensive, flexible web app technology means superior service that meets the needs of expanding cannabis community and industry Powerful web app based engine offers unique search functionality, profile building and networking capabilities for cannabis cultivators, brands, dispensaries and all associated service-related industries U.S. legal cannabis market projected to reach more than $23 billion in consumer spending by 2022 NUGL app gives consumers easy-to-locate info on all things cannabis, with unbiased reviews connecting users to their favorite brands, locations Serving international markets with no geographic limitations thanks to innovative, first-to-market technology NUGL Inc. (OTC: NUGL), the cannabis industry’s new standard of…

FridayAug 17, 2018 11:33 am

CytoDyn Inc. (CYDY) is “One to Watch”

PRO 140 is a leading monoclonal antibody/viral-entry inhibitor therapy under development for two different Human Immunodeficiency Virus (HIV) indications and is also being pursued for multiple opportunities in other immunologic indications such as autoimmune disease, chronic inflammation, certain cancers, and transplant rejection During 2017, 1.8 million people became newly infected with HIV, bringing the global total to 36.9 million people living with HIV (World Health Organization) Market potential for PRO 140 used as an anti-viral agent in combination with HAART is $1.2 billion; as a monotherapy maintenance/single-drug therapy the market is estimated at $3.8 billion CytoDyn Inc. (OTCQB: CYDY) is…

ThursdayAug 16, 2018 1:44 pm

PreveCeutical Medical Inc.’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Medicinal Cannabis Division Targets Treatment Option for Anxiety Disorders

Anxiety is implicated in several chronic physical illnesses including heart disease, respiratory disorders and gastrointestinal conditions Scientific evidence in several studies shows that CBD exhibits anti-inflammatory and anti-anxiety properties Newly created medicinal cannabis division will focus on development of cannabinoids as preventative treatment for anxiety disorders Use of PreveCeutical’s proprietary Sol-gel nasal delivery platform for cannabinoid therapy promises ease of use, sustained release, better efficacy Preventative medicine industry represents a $3.8 trillion market Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is tackling a topic that many people hesitate to bring up – anxiety disorders, including…

ThursdayAug 16, 2018 1:19 pm

First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF) Optimistic about Iron Creek Expansion as EV Market Continues Exponential Growth

Company accelerates drilling activities at Idaho site with the installation of two new drill rigs Drilling from underground successfully extending mineralization of Waite Zone U.S. needs to add 14 million plug-in electric vehicles and more than 300,000 public charging outlets by end of 2025 to meet Paris Agreement goals The United States needs to ramp up production of electric vehicles considerably in order to meet Paris Agreement target goals by 2025. This market growth is expected to translate into an overall higher demand for cobalt, one of the key components of the lithium-ion batteries that power electric vehicles, making clean,…

ThursdayAug 16, 2018 12:58 pm

Zenergy Brands, Inc. (ZNGY) Leading the Way for Companies Wishing to Invest in Energy Efficiency

30 percent of energy used in commercial buildings is wasted, an issue that most businesses wish to address Cost of energy-efficient renovation is daunting for most companies Zenergy’s Zero Cost Program makes it possible for businesses of all sizes to reduce utility consumption by 20 to 60 percent According to the U.S. Environmental Protection Agency, 30 percent of the energy used in commercial buildings is wasted. The commercial building sector is the largest user of energy and emitter of greenhouse gasses in the U.S., and the U.S. is currently the largest global user of energy. Sustainable investments toward energy efficiency…

ThursdayAug 16, 2018 11:37 am

Pressure BioSciences Inc. (PBIO) Reports Significant Financial and Operational Achievements during Highly Successful Q2

Pressure BioSciences Inc. announced strong financial results for the second quarter of 2018, demonstrating the company’s growth and stability Products and services revenue increased for the tenth consecutive quarter (YoY) while registering growth of 29 percent compared to Q2 2017 Company sets all-time first half fiscal year total revenue record A partnership with Ohio State University will enable the company to seek expansion in new industries like food, beverages, pharmaceuticals and cosmetics Pressure BioSciences Inc. (OTCQB: PBIO) recently announced its financial results for the second quarter of 2018, highlighting one of the most successful periods in the history of the…

ThursdayAug 16, 2018 11:27 am

Independent Researchers at SeeThruEquity Take Note of Advances at Payment Solutions Company Net Element, Inc. (NASDAQ: NETE)

Rise in transaction volume, product enhancements and asset acquisition show Net Element’s ongoing growth strategy SeeThruEquity labels Net Element an ‘intriguing’ high-risk, high-reward growth company with stable share price target Since 2014, Net Element’s revenues from payment processing services have nearly tripled A series of optimistic developments for payment tech processor Net Element, Inc. (NASDAQ: NETE) has led independent equity research firm SeeThruEquity to issue an update of its coverage on the company (http://ibn.fm/7NBjg). The research firm is taking note of Net Element’s forecast for an increase in gross profits based on its acquisition of services assets from partner Universal Payment…

WednesdayAug 15, 2018 12:41 pm

CytoDyn Inc. (CYDY) Sees Promising HIV Treatment Trial Results, Gets Go-Ahead to Raise Dosage

Response rate to PRO 140 rose from 40 percent at 350mg dose to 70 percent at 525mg Institutional Review Board (IRB) allows trials of viral-entry inhibitor to continue at 700mg dose PRO 140 is an FDA fast-track candidate Following clinical trial results showing that its new anti-HIV treatment is more effective at higher dosages, biotechnology company CytoDyn Inc. (OTCQB: CYDY) is set to give trial participants an increased weekly dose of PRO 140 (http://ibn.fm/oyLRe). The latest round of trial results showed that the response rate among trial participants treated with the viral-entry inhibitor rose from 40 percent at a 350mg weekly…

WednesdayAug 15, 2018 12:17 pm

MIDS Cardiac by Zenosense, Inc. (ZENO): A Heart Attack Diagnostic Revolution?

The handheld testing device technology under development by Zenosense aims to deliver rapid results and state-of-the-art, laboratory-accurate results for the quick diagnosis of heart attacks Medical professionals believe that diagnosis within 30 minutes of a heart attack is the golden standard for ensuring adequate treatment Cardiac diagnostic testing market estimated between $2 billion and $6 billion in the U.S. alone MIDS Cardiac™, a handheld diagnostic device for cardiac emergency triage being developed by Zenosense, Inc. (OTCQB: ZENO), could prove to be revolutionary in the diagnostic process. Incorporating the patented MIDS technology, which is predicated on the nano-magnetic detection of assay…

Site Search

Company Search

Category: News